Die Weiterentwicklung einer intermediate variety des Deutschen bei Nachfahren nordböhmischer Herkunft in Rio Grande do Sul, Brasilien
Angélica Prediger, Maria Habel
0 citationsRevista Linguagem & Ensino
Maria Habel
Informations fournies par OpenAlex. Research Africa ne déduit ni nationalité, ni poste, ni coordonnées personnelles.
14Publications signalées
275Citations signalées
1Affiliations récentes
Institutions déclarées
Domaines associés
COVID-19 Clinical Research StudiesComplement system in diseasesSARS-CoV-2 and COVID-19 ResearchHidradenitis Suppurativa and TreatmentsLong-Term Effects of COVID-19
Publications récentes
87. The safety and efficacy advantage of blocking C5a vs C5 in critically ill, COVID-19 patients: Results from PANAMO, a Phase 3 randomized controlled trial
Bruce Burnett, Endry H. T. Lim, Alexander P. J. Vlaar, Sanne de Bruin et autres
0 citationsOpen Forum Infectious Diseases
Vilobelimab’s effect on mortality in severe COVID-19 ARDS patients: Phase 3 RCT
Alexander P. J. Vlaar, Endry H. T. Lim, Djillali Annane, Martin Witzenrath et autres
0 citations
Pharmacokinetic analysis of vilobelimab, anaphylatoxin C5a and antidrug antibodies in PANAMO: a phase 3 study in critically ill, invasively mechanically ventilated COVID-19 patients
Endry H. T. Lim, Alexander P. J. Vlaar, Sanne de Bruin, Simon Rückinger et autres
8 citationsIntensive Care Medicine Experimental
Anti-C5a Vilobelimab Reduces All-cause Mortality in Critically Ill COVID-19 Patients and in Those With Severe ARDS: A Phase 3 Randomized Double-blind, Placebo-controlled Study
Martin Witzenrath, A.P.J. Vlaar, Michael Bauer, D. Annane et autres
2 citations
Anti-C5a antibody vilobelimab treatment and the effect on biomarkers of inflammation and coagulation in patients with severe COVID-19: a substudy of the phase 2 PANAMO trial
Endry H. T. Lim, Alexander P. J. Vlaar, Lieuwe D. J. Bos, Lonneke A. van Vught et autres
18 citationsRespiratory Research
LB1529. Randomized, Controlled Phase 3 Study of anti-C5a Vilobelimab's Effect on Mortality in Critically Ill COVID-19 Patients: A Therapy for Viral Pneumonia
Bruno Mourvillier, Alexander P. J. Vlaar, Martin Witzenrath, Michael Bauer et autres
0 citationsOpen Forum Infectious Diseases
Elevated Plasma Complement Proteins in Palmoplantar Pustulosis: A Potential Therapeutic Target
Afsáneh Alavi, Michelle A. Lowes, Justin D. Lu, Zhongli Xu et autres
3 citationsJournal of Cutaneous Medicine and Surgery
Controlling complement 5a (C5a) in disease setting requires a specifically targeted inhibition
Renfeng Guo, Maria Habel, Jana Ziereisen, Marlen Hermann et autres
0 citationsMolecular Immunology
Complement in hidradenitis suppurativa
Theodora Kanni, O. Zenker, Maria Habel, Niels C. Riedemann et autres
0 citationsBritish Journal of Dermatology
Complement activation in hidradenitis suppurativa: a new pathway of pathogenesis?
Theodora Kanni, O. Zenker, Maria Habel, Niels C. Riedemann et autres
80 citationsBritish Journal of Dermatology
Controlling the anaphylatoxin C5a in diseases requires a specifically targeted inhibition
Niels C. Riedemann, Maria Habel, Jana Ziereisen, Marlen Hermann et autres
52 citationsClinical Immunology
BNTIC News n’est pas le producteur de ces données. Recherche à la demande dans Crossref, OpenAIRE, DOAJ, Europe PMC, HAL, DataCite, ROR et la Banque mondiale, sans clé ; OpenAlex reste optionnel. Aucun service payant requis, aucune donnée externe enregistrée en base. Sources et limites.